In many cancers, the phosphatidylinositol 3-kinase (PI3K) signaling pathway is persistently activated due to genetic mutations, while certain wild-type PI3K proteins adopt active conformations that further enhance the pathway’s oncogenic potential. This evidence concerns the gene PIK3CG and cancer.